Background: This study aimed to investigate the potential effect of adjuvant chemotherapy in patients diagnosed with stage IB gastric adenocarcinoma (GAC). Method: A total of 1727 patients were included in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 and divided into the chemotherapy and no-chemotherapy groups. Then, the methods of Kaplan-Meier analysis, propensity score matching (PSM), and competing risk analysis were implemented. Results: After PSM, no significant difference was found in the chemotherapy and no-chemotherapy groups in overall survival (OS) (p=0.4) and cancer-specific survival (CSS) (p=0.12) in survival curves. The competing risk analysis presented that the 5-year cumulative incidence of cancer-specific death (CSD) was significantly lower in patients receiving chemotherapy (11.5% vs. 20.8%, p=0.007), while no significant discrepancy was observed in other causes of death (OCD) in both groups (10.6% vs. 10.9%, p=0.474). Multivariable competing risks regression models presented a significant correlation between chemotherapy and CSD (HR, 0.51; 95%CI, 0.31–0.82; p=0.007). Conclusion: The stage IB GAC patients can benefit from adjuvant chemotherapy based on this competing risk analysis.
CITATION STYLE
Xie, Y., Du, D., Song, X., Li, X., Ni, Z., & Huang, H. (2022). The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis. World Journal of Surgical Oncology, 20(1). https://doi.org/10.1186/s12957-022-02591-5
Mendeley helps you to discover research relevant for your work.